Pharmacomicrobiomics: From Host–Microbiome–Drug Interactions to Clinical Translation in Precision Medicine
Metabolites · 23.08.2026 · 16 (9) · 602
DOI: 10.3390/metabo16090602 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 23.08.2026. Verfasst von Guilherme Araújo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, University of Coimbra, 3000-458 Coimbra, Portugal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Pharmacy of the University of Coimbra and co-funded by the EU Recovery and Resilience Facility and Portuguese national funds.
Abstract (Originalsprache)
Marked interindividual variability in drug response remains a major challenge in clinical pharmacology and cannot be fully explained by host genetics alone. Increasing evidence indicates that the gut microbiota constitutes an additional determinant of drug efficacy and toxicity through bidirectional interactions with pharmacological therapies. This recognition has led to the emergence of pharmacomicrobiomics, a field that investigates how microbial communities influence drug disposition and response, and how drugs, in turn, alter the microbiome. Microbiome-mediated effects on drug efficacy and toxicity have been described across several therapeutic areas, including oncology, multiple sclerosis, and type 2 diabetes mellitus. Although these findings are promising, most mechanistic evidence derives from preclinical and animal studies, with relatively limited validation in controlled clinical trials. Strategies to modulate the gut microbiota, including prebiotics, probiotics, and faecal microbiota transplantation, have shown preliminary promise in optimising drug efficacy and reducing adverse effects, although methodological heterogeneity and incomplete mechanistic understanding limit their current clinical application. The identification of robust microbiome-derived biomarkers and the integration of multi-omics approaches, particularly metabolomics, are expected to accelerate the translation of pharmacomicrobiomics into precision medicine. This review summarises current evidence regarding microbiome–drug interactions, the mechanisms underlying microbiome-mediated modulation of pharmacokinetics and pharmacodynamics, emerging therapeutic strategies, and the challenges that remain before pharmacomicrobiomics can be implemented in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Pharmacy, University of Coimbra, 3000-458 Coimbra, Portugal.
- CNC-UC-Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal.
- CiBB-Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, 3004-548 Coimbra, Portugal.
- Department of Medical and Health Sciences, School of Health and Human Development, University of Évora, 7004-516 Évora, Portugal.
- Comprehensive Health Research Centre (CHRC), University of Évora, 7004-516 Évora, Portugal.
ORCID-Profile: Sara Domingues, Gabriela Jorge da Silva, Tiago Lima
Förderung
- Faculty of Pharmacy of the University of Coimbra and co-funded by the EU Recovery and Resilience Facility and Portuguese national funds
Zitieren
APA
Araújo, G., Domingues, S., da Silva, G. J., & Lima, T. (2026). Pharmacomicrobiomics: From Host–Microbiome–Drug Interactions to Clinical Translation in Precision Medicine. Metabolites, 16(9), 602. https://doi.org/10.3390/metabo16090602
Vancouver
Araújo G, Domingues S, da Silva GJ, Lima T. Pharmacomicrobiomics: From Host–Microbiome–Drug Interactions to Clinical Translation in Precision Medicine. Metabolites. 2026;16(9):602. doi:10.3390/metabo16090602
BibTeX
@article{Arajo2026,
author = {Araújo, Guilherme and Domingues, Sara and da Silva, Gabriela Jorge and Lima, Tiago},
title = {Pharmacomicrobiomics: From Host–Microbiome–Drug Interactions to Clinical Translation in Precision Medicine},
journal = {Metabolites},
year = {2026},
volume = {16},
number = {9},
pages = {602},
doi = {10.3390/metabo16090602}
}
EUVIMED